In this study, we chose LVs as a delivery system for human PD-L1 targeting sdAbs, as LVs were previously shown to efficiently deliver their cargo to mainly tumor cells upon intratumoral delivery,31 and because LVs have been used in a clinical setting for therapy for primary immunodeficiencies and cancers.32 The gene discussed is CD274; the disease is cancer.